Depression News and Research

Latest Depression News and Research

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

Health situation grim as Greece weathers economic crisis

Researchers warn that the health of people in Greece could be in danger in the wake of the financial crisis. Writing in The Lancet, they said cuts to hospitals' budgets meant they were being overstretched.

11 Oct 2011

NovaSom enters unique agreement with HealthAmerica to treat sleep disorders

NovaSom, Inc., the market leader in technology-driven, payer-aligned cost-saving solutions for obstructive sleep apnea (OSA) management, today announced it has entered a preferred relationship to aid HealthAmerica with managing its sleep disorder diagnostic expenses.

11 Oct 2011

Many cancer survivors continue to have poorer health years after completion of treatment

Forty-five per cent of cancer survivors in Northern Ireland suffer from physical and mental health problems years after their treatment has finished, according to new research from Macmillan Cancer Support and Queen's University Belfast.

11 Oct 2011

Cannabis use leads to increased risk of depression in young people with specific genotype

Young people who are genetically vulnerable to depression should be extra careful about using cannabis: smoking cannabis leads to an increased risk of developing depressive symptoms.

10 Oct 2011

Boehringer Ingelheim receives FDA approval for COMBIVENT RESPIMAT to treat COPD

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved COMBIVENT RESPIMAT, a new, propellant-free inhaler product that uses a slow-moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler.

10 Oct 2011

BDNF methionine variation increases risk of suicidal behaviour

A new study from the Centre for Addiction and Mental Health has found evidence that a specific gene is linked to suicidal behaviour, adding to our knowledge of the many complex causes of suicide. This research may help doctors one day target the gene in prevention efforts.

10 Oct 2011

Art, drama and dance may benefit dementia sufferers

While medical researchers continue the search for advanced diagnosis, prevention and treatment of dementia, a researcher at Royal Holloway, University of London is focusing on improving the experiences of those already suffering with the devastating disease for whom any cure would be too late.

7 Oct 2011

BDNF met variation gene linked to suicidal behaviour

7 Oct 2011

New $13.75M data-mining project to better understand factors behind mental disorders

Chicago will be home to a new $13.75 million project that will apply data mining methods to better understand the genetic and environmental factors behind neuropsychiatric disorders.

7 Oct 2011

Study proposes an integrative dynamic model of depression-CAD relationship

This study proposes an integrative dynamic model of the depression-coronary artery disease (CAD) relationship. This model may have potential for integrating findings regarding the depression-CAD relationship, contributing to the clarification of discords on screening and treatment of depression, and guiding future research.

7 Oct 2011

Depression frequently seems to uncouple 'Hate Circuit' in the brain

A new study using MRI scans, led by Professor Jianfeng Feng, from the University of Warwick's Department of Computer Science, has found that depression frequently seems to uncouple the brain's "Hate Circuit".

4 Oct 2011

Phagenesis closes Series B funding

Phagenesis Ltd, the global leader in the treatment of dysphagia (inability to swallow safely) today announced that it has closed a €7 million Series B funding round designed to accelerate the company's development plans.

4 Oct 2011

New data on long-term use of antidepressant drugs

There is increasing awareness that, in some cases, long-term use of antidepressant drugs (AD) may enhance the biochemical vulnerability to depression and worsen its long-term outcome and symptomatic expression, decreasing both its likelihood of subsequent response to pharmacological treatment and the duration of symptom-free periods. A review of literature suggesting potential side effects during long treatment with antidepressant drugs was performed.

3 Oct 2011

Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation

Alkermes plc today announced the initiation of a phase 2b study of ALKS 37, an orally active, peripherally restricted opioid antagonist for the treatment of opioid-induced constipation.

3 Oct 2011

Study sheds new light on relationship of anxiety and high blood pressure to primary aldosteronism

A study that has been published in the Journal of Clinical Endocrinology and Metabolism by an Italian group headed by Nicoletta Sonino (Padova) sheds some new light on the relationship of anxiety and high blood pressure to a hormonal disturbance, primary aldosteronism.

3 Oct 2011

Mild stroke patients may live with hidden disabilities: Study

On the surface they appear unaffected, but people who have mild strokes may live with hidden disabilities, including depression, vision problems and difficulty thinking, according to a study released today at the Canadian Stroke Congress.

3 Oct 2011

Scientists use Twitter to detect global mood changes

A novel study has used Twitter streams from 2.4 million people around the globe to take their emotional temperature found that people start the day in a good mood. But it decreases as work starts, then improves when work ends.

2 Oct 2011

Scientists discover that DNA modifications in brain cells change due to stimulated brain activity

Johns Hopkins scientists investigating chemical modifications across the genomes of adult mice have discovered that DNA modifications in non-dividing brain cells, thought to be inherently stable, instead underwent large-scale dynamic changes as a result of stimulated brain activity.

1 Oct 2011

Novel binding assay can simplify search for potential SERT inhibitors

Many psychiatric conditions are caused by aberrant metabolism of the neurotransmitter serotonin. Researchers in the Department of Pharmacy at LMU have now developed a new screening method, which will facilitate the search for new drugs that modulate the biological activity of serotonin.

1 Oct 2011